Mitral valve replacement the patient on cardiopulmonary bypass. In a study of 99 patients who had mitral valve surgery for regurgitation from January 1990 to June 1996, overall mortality was 4%, which included 3 operative deaths and 4 late deaths. Overall 5-year survival rate was 92%. With mitral valve replacement surgery, there are risks such as bleeding, infection or reaction to anesthesia. Risks depend on a patient’s age, general condition, specific medical conditions, and heart function. Neuropsychological and psychopathologic changes following mitral valve replacement surgery have been recognized from the very beginning of modern heart surgery. Variables correlated with nonpsychotic mental disorder after
Mitral valve stenosis asymptomatic patients. The treatment options for mitral stenosis include medical management, mitral valve replacement by surgery, and percutaneous mitral valvuloplasty by balloon catheter. The indication for invasive treatment with either a mitral valve replacement or valvuloplasty is NYHA functional class III or IV symptoms. Another option is balloon dilatation. To determine which patients would benefit from percutaneous balloon mitral valvuloplasty, a scoring system has been developed. Scoring is based on 4 echocardiographic criteria: leaflet mobility, leaflet thickening, subvalvar thickening, and calcification. Individuals with a score of ≥ 8 tended to have suboptimal results. Superb results with valvotomy are seen in